CIS injection, like other antineoplastic drugs such as paclitaxel, vincristine, and oxaliplatin, activates the NLRP3 inflammasome, which in turn promotes the synthesis of proinflammatory cytokines, resulting in neuropathic pain and muscle wasting [16]. This evidence concerns the gene NLRP3 and in situ carcinoma.